Impact Factor
Call For Paper
Volume 12 Issue 07
July 2026
Author(s)
Abstract
For The Treatment Of Acid Reflux Disease (GERD), Functional Dyspepsia, And Acid Reflux Disorders, Doctors Frequently Prescribe The Fixed-dose Combination (FDC) Of Omeprazole, A Proton Pump Inhibitor (PPI), And Dopamine D2 Receptor Antagonist, Domperidone, Which Has Prokinetic And Antiemetic Effects. By Enhancing Stomach Motility And Decreasing Gastric Acid Secretion At The Same Time, This Combination Has A Synergistic Therapeutic Effect. However, Due To Differences In Formulation Design, Enteric Coating Technologies, And Manufacturing Standards, Different Marketed Formulations Of This FDC May Have Different Pharmaceutical Quality And Therapeutic Consistency. These Variations May Have A Major Effect On The Release Of The Drug, Its Bioavailability, And Eventually Its Clinical Effectiveness.
Keywords
Paper ID
IJSARTV11I5103597
Publication Date
May 18, 2025
Research Area
NA